Agios Pharmaceuticals, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $55.4 million (+330.0% year over year) and diluted EPS of -$1.09. It usually reports 29–43 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 29–43 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
55
+330.0%
|
-65
+37.1%
|
-1.09
+38.8%
|
|
Jul 30, 2026
30 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
45
+259.3%
|
-101
+10.1%
|
-1.69
+12.4%
|
|
Apr 29, 2026
29 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
21
+137.7%
|
-99
-11.0%
|
-1.69
-9.0%
|
|
Feb 12, 2026
43 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
20
+86.1%
|
-108
-11.9%
|
-1.85
-12.8%
|
|
Oct 30, 2025
30 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
13
+43.7%
|
-103
-110.9%
|
-1.78
-111.0%
|
|
Jul 31, 2025
31 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
12
+44.6%
|
-112
-16.5%
|
-1.93
-14.2%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
9
+6.6%
|
-89
-9.5%
|
-1.55
-6.9%
|
|
Feb 13, 2025
44 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
11
+51.1%
|
-97
-0.6%
|
-1.64
+4.3%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AGIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1439222
- Former names
- AGIOS PHARMACEUTICALS INC (until Jul 16, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.